Archive

Each participating hospital also selected one of the seven available value metrics for evaluation based on rates of utilization: cardiac rehabilitation after CABG, cardiac rehabilitation after PCI, 7-day follow-up after CHF, 14-day follow-up after COPD, 7-day follow-up after pneumonia, 14-day follow-up after sepsis, and preoperative testing. Figure 3 illustrates that the value metric selected by the most hospital members was the newly introduced 14-day follow-up after sepsis metric (19) and this was followed by cardiac rehabilitation after PCI (16). Both of these metrics align with the work and measures used at peer CQIs (HMS and BMC2, respectively). Compared to selections from the previous PY 2024-2025 cycle, the number of hospitals that selected preoperative testing doubled from 6 to 13, while selections for 7-day follow-up after CHF decreased from 24 to 15. None of the hospitals selected 7-day follow-up after pneumonia, and the number of hospitals that chose cardiac rehabilitation value metrics did not change much between program cycles.

As seen in Figure 4, there was variation in the distribution of value metric selections by MVC region. Regions 1 & 3 observed similar trends with 14-day follow-up after sepsis selected the most and cardiac rehabilitation after CABG selected by none of the sites. Cardiac rehabilitation after PCI was the most selected value metric in region 4, followed by preoperative testing. In region 2, both preoperative testing and 7-day follow-up after CHF were the most selected value metrics.

What is staying the same from PYs 2024-2025?

Similar to the PY 2024-2025 cycle, hospitals will continue to be scored out of 10 points maximum. They will also continue to be evaluated on their risk-adjusted, price-standardized total episode spending for a selected condition; their rate for a selected value metric; and their engagement in MVC activities. Hospitals can continue to select coronary artery bypass graft (CABG), congestive heart failure (CHF), or chronic obstructive pulmonary disorder (COPD) for episode spending scoring. Similarly, most of the value metric options remain the same with changes in definition for only the preoperative testing and sepsis value metrics.

Each hospital’s episode spending and value metric selections will continue to be scored on improvement compared to the hospital’s own past performance as well as on achievement relative to an MVC cohort. Each hospital will continue to be awarded the greater of the two scores, either improvement or achievement, which are calculated using Z-scores. Cohort designation is still based on bed size, critical access status, and case mix index.

What is changing for PYs 2026-2027?

While the overall program structure will be scored to a maximum of 10 points (Figure 2), the scoring within the components varies from PY 2024-2025. The PY 2026-2027 cycle is made up of a maximum of three points from an episode spending metric, a maximum of four points from a value metric, a maximum of two points from engagement activities, and a maximum of one point from a health equity measure (a new component). For this cycle, hospitals will need to select an episode spending condition and a value metric. The health equity and engagement activities do not require selection. Eligibility for selections are determined based on case counts. To be eligible to select a condition or value metric, a hospital must have at least 20 cases in the full baseline year of 2023.

Although three episode spending conditions offered in PYs 2024-2025 will continue to be options in PYs 2026-2027 (i.e., CABG, CHF, COPD), MVC retired colectomy (non-cancer), joint replacement, and pneumonia from its episode spending menu. In addition, MVC is adding percutaneous coronary intervention (PCI) as an episode spending condition. The full menu of episode spending conditions for PYs 2026-2027 will be CABG, CHF, COPD, and PCI.

MVC is also modifying two of its value metrics. The sepsis value metric in PYs 2026-2027 will be 14-day follow-up after sepsis rather than 30-day risk-adjusted readmissions after sepsis. This change is more closely aligned with the HMS incentive for increasing post-discharge care coordination. The preoperative testing value metric definition will also be different in PYs 2026-2027. The first change is that all three included procedures (i.e., laparoscopic cholecystectomy, inguinal hernia repair, and lumpectomy) will be combined for scoring. Previously, each procedure was treated separately, and hospitals were scored on the best of the three. The second change is that lab testing will be included in the definition. Previously, preoperative lab tests such as complete blood count, metabolic panel, coagulation studies, and urinalysis were not included in calculating the testing rate prior to the three procedures. Going forward, MVC will identify preoperative testing that occurs in the 30 days prior to MVC-defined laparoscopic cholecystectomy, inguinal hernia repair, and lumpectomy for any of the following tests: complete blood count, basic metabolic panel, comprehensive metabolic panel, coagulation studies, electrocardiogram, echocardiogram, cardiac stress test, chest x-ray, pulmonary function test, and urinalysis.

Brand new in PY 2026-2027 will be the addition of a claims-based health equity measure, for which hospitals will be assessed using an index of disparity (Figure 3). The index of disparity (IOD) will measure the spread of 30-day risk-adjusted all cause readmission rates for medical conditions among different payer categories within their hospital. Scoring for this measure will begin in PY 2026, but hospitals will begin to see sample scoring for this measure on their PY 2025 scorecards. Hospitals can earn the health equity point through both improvement and achievement pathways, similar to their episode spending and value metric selections.